Novo Nordisk teams up with Kymab in an antibody discovery agreement.
Kymab, a monoclonal antibody biopharmaceutical company, have announced an agreement in therapeutic antibody discovery. Novo Nordisk has been granted a non-exclusive license to Kymab’s proprietary Kymouse human antibody discovery platform to discover, develop and commercialize therapeutic monoclonal antibody drugs for human diseases.
The license will provide Novo Nordisk with access to the Kymouse HK and Kymouse HL transgenic human antibody mouse strains, which can generate human antibody drug candidates. The Kymouse HL strain produces antibodies with human heavy and lambda light chains whereas Kymouse HK generates antibodies with human heavy and kappa light chains.
“Antibody therapeutics have great potential to advance patient care in diseases with significant unmet medical need. Kymab’s highly innovative and technically advanced Kymouse platform is an excellent fit with our existing therapeutic antibody discovery capability,” said Hanne Risager Romedahl, Vice President, Head of ImmunoTechnology, Novo Nordisk.
The financial terms of the agreement were not disclosed, but include platform license fees, development milestone payments for drug candidates and royalties on sales of antibodies discovered using the Kymouse strains.
